Brian Jahns Email and Phone Number
Brian Jahns work email
- Valid
- Valid
- Valid
- Valid
- Valid
Brian Jahns personal email
Brian Jahns phone numbers
I believe that we succeed only if we place patients at the centre of everything we do. I deeply understand the needs of patients, and use this insight to help save lives. I've worked successfully on both sides of the pharma equation: as healthcare provider, and as pharma executive working in commercial and medical roles.I bring a strategic mindset to the table, and am able to prioritize and execute with limited resources. I'm able to roll up my sleeves and carry out tactical work needed to execute while simultaneously providing the strategic thinking necessary to fulfill a corporate vision.My values enable me to grow, coach effectively, and drive results. I model authenticity, passion, and integrity. By modelling authenticity and approachability, I engage customers and employees to focus on a vision of improving patient outcomes. In my experience, great ideas come from a variety of sources. By being approachable and authentic, I maximize the value that individuals offer, and I spur them to act with more confidence.I communicate passion for my work, and inspire others to greatness. I believe that as a healthcare provider, I used to care for patients one at a time. Now, as a corporate leader in biotech, I deliver on the promise of personalized medicine and care for patients on a broader scale. By valuing and modelling integrity, I motivate others to act ethically.Together, we put the interests of patients and the organization first, and we generate value in an ethical and sustainable manner.Contact me at: bejahns(@)gmail.com
Vasomune Therapeutics, Inc.
View- Website:
- vasomune.com
- Employees:
- 9
-
President, And Chief Executive OfficerVasomune Therapeutics, Inc.Toronto, On, Ca
-
President, And Chief Operating OfficerVasomune Therapeutics, Inc. May 2023 - PresentToronto, Ontario, Ca
-
Consultant In Oncology And Rare Diseases Biotechnology And Managing Director, Dyneq Consulting Inc.Dyneq Consulting Inc. Jul 2016 - PresentDynamic Equilibrium: Early stage biotech companies will appreciate our ability to integrate science, and patient and stakeholder needs with business priorities. We provide strategic insight and direction, and execute decisively. Decades of experience and success have enabled us to develop capability and expertise in:- Strategic planning,- Oncology development and commercialization,- Rare and orphan disease therapeutics development and commercialization,- Licensing and partnering. -
Board Director, N-Zyme Biomedical Inc.N-Zyme Biomedical Inc. Dec 2022 - Dec 2023Vancouver, British Columbia, Ca -
Board Director, Sauvie Bike LlcSauvie Inc. Dec 2022 - Dec 2023 -
Chief Operating Officer, Sauvie Inc.Sauvie Inc. Feb 2022 - Dec 2023Sauvie Inc. is an emerging global biopharma company executing a diversified risk, high growth strategy in immuno-oncology development and commercialization.
-
Senior Vice-President, Commercial And Business DevelopmentTrillium Therapeutics Inc. Oct 2016 - Dec 2019Cambridge, Ma, UsTrillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, TTI-621, is a SIRPaFc fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (“do not eat”) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (“eat”) signals. A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides (NCT02890368). TTI-622 is an IgG4 SIRPaFc protein, which is primarily being developed for combination therapy. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. Stemming from this platform, the company’s most advanced preclinical programs are: 1. STING agonist, TTI-10001, a non-cyclic dinucleotide STING agonist that may be dosed intratumorally, intravenously, and orally. 2. TTI-2341, an orally-available epidermal growth factor receptor (EGFR) antagonist with increased uptake and retention in the brain. In addition, a number of compounds directed at undisclosed immuno-oncology targets are currently in the discovery phase. -
Vice-President, Sales And Marketing, Oncology (Canada) & Vice-President, Product Strategy (Canada)Roche Aug 2011 - Jul 2016Switzerland 🇨🇭 , Ch• Led twenty-three marketing and fifty-one field reports in the successful launches of Gazyva, Zelboraf, Erivedge, Perjeta, Kadcyla, and Cotellic.• Active in the Canadian Leadership Team executive committee reporting to the CEO.• Led the design and implementation of marketing strategy, sales promotion and local life-cycle team management for Rituxan, Herceptin, Avastin, Xeloda, and Tarceva. As a result, grew sales from $420M in 2011 to $560M in 2015, achieving standings of 1st, 2nd, and 3rd largest Canadian brands in the hospital space.• Led marketing development of product digital channels and social media plans.• These efforts resulted in the successful uptake of Perjeta in first line metastatic HER2+ve breast cancer. These efforts also resulted in the successful launch of Zelboraf complimented by a unique national melanoma BRAF testing service.• Led the Key Account Management function, an innovative Pharma and Diagnostics partnership designed to augment the corporate value proposition and relationships with senior hospital stakeholders, including the C-suite.• Led focus on enhancing customer value and satisfaction.• Active in a wide range of critical organizational activities including the Roche 2020 corporate reorganization, which positioned marketing and sales for greater future success. The result of these efforts was a reorganization in commercial staff that enabled the organization to service customers in a more efficient manner. -
Business Unit Director, HematologyRoche Nov 2006 - Aug 2011Switzerland 🇨🇭 , Ch
-
Marketing Director, HematologyRoche Jan 2006 - Nov 2006Switzerland 🇨🇭 , Ch
-
Associate Medical Director, Hematology & OncologyRoche Apr 2003 - Jan 2006Switzerland 🇨🇭 , Ch
-
Marketing And Sales Manager, VirologyRoche Jan 2001 - Apr 2003Switzerland 🇨🇭 , Ch
-
Associate Medical Director, Infectious DiseasesRoche Oct 1998 - Dec 2001Switzerland 🇨🇭 , Ch
-
Senior AssociatePhase 4 Health Inc Jan 1997 - Oct 1998
-
Vice Chair, Ethics Review CommitteeIntegrated Research Inc. Jan 1996 - Jan 1998
-
Clinical Instructor, Doctor Of Pharmacy ProgramUniversity Of Toronto Jan 1995 - Jan 1997Toronto, Ontario, Ca -
Faculty Member Of Research Ethics BoardSt. Michael'S Hospital Jan 1996 - Dec 1996Toronto, Ontario, Ca -
Clinical Pharmacy Specialist, Trauma And Neurosurgical Intensive Care UnitSt. Michael'S Hospital May 1995 - Dec 1996Toronto, Ontario, Ca
-
Research Fellow, Dept Of Pharmacy Practice, & Clinical Associate, Program In Emergency MedicineUniversity Of Illinois At Chicago 1993 - 1995Chicago, Il, Us -
Pharmacy Practice Resident, Detroit Receiving HospitalDetroit Medical Center 1992 - 1993Detroit, Michigan, Us
Brian Jahns Skills
Brian Jahns Education Details
-
Queen'S UniversityExecutive Program -
Wayne State UniversityDoctor Of Pharmacy - Pharmd
-
Wayne State UniversityBachelor Of Pharmacy - Bpharm
-
Western UniversityBachelor Of Science - Bs
-
InseadPharma Marketing Program
-
Saïd Business School, University Of Oxford2021
Frequently Asked Questions about Brian Jahns
What company does Brian Jahns work for?
Brian Jahns works for Vasomune Therapeutics, Inc.
What is Brian Jahns's role at the current company?
Brian Jahns's current role is President, and Chief Executive Officer.
What is Brian Jahns's email address?
Brian Jahns's email address is br****@****che.com
What is Brian Jahns's direct phone number?
Brian Jahns's direct phone number is +197323*****
What schools did Brian Jahns attend?
Brian Jahns attended Queen's University, Wayne State University, Wayne State University, Western University, Insead, Saïd Business School, University Of Oxford.
What are some of Brian Jahns's interests?
Brian Jahns has interest in Tdi Tech And Decompression Scuba, Children, Tdi Tech And Raid Decompression Scuba, Padi Scuba Certified, Education, Science And Technology, Animal Welfare, Ssi Rescue, Arts And Culture, Health.
What skills is Brian Jahns known for?
Brian Jahns has skills like Oncology, Pharmaceutical Industry, Biotechnology, Pharmaceutical Sales, Clinical Trials, Infectious Diseases, Hematology, Strategy, Leadership, Cross Functional Team Leadership, Biopharmaceuticals, Product Launch.
Who are Brian Jahns's colleagues?
Brian Jahns's colleagues are Gosia Hodgson, Cpa, Ca, Harold Kim.
Free Chrome Extension
Find emails, phones & company data instantly
Aero Online
Your AI prospecting assistant
Select data to include:
0 records × $0.02 per record
Download 750 million emails and 100 million phone numbers
Access emails and phone numbers of over 750 million business users. Instantly download verified profiles using 20+ filters, including location, job title, company, function, and industry.
Start your free trial